Peripheral versus central modulation of gastric vagal pathways by metabotropic glutamate receptor 5.
Metabotropic glutamate receptors (mGluR) are classified into group I, II, and III mGluR. Group I (mGluR1, mGluR5) are excitatory, whereas group II and III are inhibitory. mGluR5 antagonism potently reduces triggering of transient lower esophageal sphincter relaxations and gastroesophageal reflux. Transient lower esophageal sphincter relaxations are mediated via a vagal pathway and initiated by distension of the proximal stomach. Here, we determined the site of action of mGluR5 in gastric vagal pathways by investigating peripheral responses of ferret gastroesophageal vagal afferents to graded mechanical stimuli in vitro and central responses of nucleus tractus solitarius (NTS) neurons with gastric input in vivo in the presence or absence of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP). mGluR5 were also identified immunohistochemically in the nodose ganglia and NTS after extrinsic vagal inputs had been traced from the proximal stomach. Gastroesophageal vagal afferents were classified as mucosal, tension, or tension-mucosal (TM) receptors. MPEP (1-10 microM) inhibited responses to circumferential tension of tension and TM receptors. Responses to mucosal stroking of mucosal and TM receptors were unaffected. MPEP (0.001-10 nmol icv) had no major effect on the majority of NTS neurons excited by gastric distension or on NTS neurons inhibited by distension. mGluR5 labeling was abundant in gastric vagal afferent neurons and sparse in fibers within NTS vagal subnuclei. We conclude that mGluR5 play a prominent role at gastroesophageal vagal afferent endings but a minor role in central gastric vagal pathways. Peripheral mGluR5 may prove a suitable target for reducing mechanosensory input from the periphery, for therapeutic benefit.
Young
Richard L
RL
Nerve-Gut Research Laboratory, Level 1 Hanson Institute, Adelaide, SA, Australia. richard.young@adelaide.edu.au
Page
Amanda J
AJ
O'Donnell
Tracey A
TA
Cooper
Nicole J
NJ
Blackshaw
L Ashley
LA
D000200:Action Potentials / Q000187:drug effects; D000344:Afferent Pathways / Q000502:physiology*; D000818:Animals; D001921:Brain / Q000502:physiology*; D001933:Brain Stem / Q000737:chemistry / Q000166:cytology / Q000502:physiology; D049630:Esophageal Sphincter, Lower / Q000294:innervation; D004947:Esophagus / Q000294:innervation; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005289:Ferrets; D008465:Mechanoreceptors / Q000187:drug effects / Q000502:physiology; D008526:Medulla Oblongata / Q000737:chemistry / Q000166:cytology / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D009620:Nodose Ganglion / Q000737:chemistry / Q000166:cytology / Q000502:physiology; D011725:Pyridines / Q000494:pharmacology; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology*; D011984:Sensory Receptor Cells / Q000187:drug effects / Q000502:physiology; D017552:Solitary Nucleus / Q000737:chemistry / Q000166:cytology / Q000502:physiology; D013270:Stomach / Q000294:innervation*; D014630:Vagus Nerve / Q000502:physiology*
D018691:Excitatory Amino Acid Antagonists; D011725:Pyridines; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate; C121465:6-methyl-2-(phenylethynyl)pyridine